Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

By J. Baselga, Carlos L. Arteaga. Journal of Clinical Oncology, 2005

736 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/383ca98171c3a966580635135f23693b265dd197

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Sliwkowski
2. R. Kerbel
3. M. Lacouture

In Pulmonary and Respiratory Medicine

1. R. Kerbel
2. N. Ferrara

Citations in the corpus

• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008, background): “A renewed interest in the role of EGFR in HER2-amplified tumors arose with the advent of small-molecule tyrosine kinase inhibitors that were designed to specifically inhibit EGFR (26, 27).”
• Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR (2009, background): “Indeed, the relative successes of targeting EGFR in human cancer may be, at least in part, attributed to the antiangiogenic properties of EGFR kinase inhibitors (EKI) and the respective neutralizing antibodies (14, 15).”